Navigation Links
Parkinson's Disease: World Drug Market 2013-2023

NEW YORK, March 4, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Parkinson`s Disease: World Drug Market 2013-2023`s-Disease-World-Drug-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Your guide to sales outlooks and R&D for treating Parkinson's Where are treatments for Parkinson's disease heading - technological and commercial outlooks? Visiongain's updated report gives you forecasted revenues to 2023 and shows you R&D trends, opportunities and industry prospects. Emerging technologies hold promise.

Our new study investigates developments, also letting you assess projected sales data at overall world market, submarket and national level. There you investigate the most promising areas in that industry and market segment for neurodegenerative disorders.

Forecasts and other analyses to help you stay ahead in knowledge

In our report you find revenue forecasting to 2023, growth rates and market shares. Also, you see qualitative analysis (SWOT), business news, outlooks and developmental trends (R&D). You receive 63 tables, 38 charts and four research interviews.

You can stay ahead in knowledge for treating that motor system disorder and benefit your research and analyses. Our work lets you discover industry dynamics and growth potentials.

Make sure you know the latest trends, innovations and opportunities. The following sections show what you find in our study.

You see prospects for the world market and submarkets

Along with predictions of overall world market value, you see revenue forecasting of five submarkets at world level. We show sales data from 2011 to 2023: • Dopaminergic agents• Dopamine receptor agonists• COMT inhibitors• MAO inhibitors• Other mechanisms of action (grouped).

With our investigation you gain research and analysis with individual sales forecasts and discussions. You find competition, commercial drivers and restraints. See what's likely to achieve the most success for treating Parkinson's disease (PD).

Our work also breaks the overall world PD forecast into leading national markets.

Prospects to 2023 for leading countries

Developments worldwide will influence the Parkinson's drug market, especially rising demand in emerging countries. There are many opportunities.

You discover individual revenue forecasts to 2023 for seven national markets and one developing market block. Find relevant overall sales:

• US


Germany, France, UK, Italy and Spain (EU5 countries)

Brazil, Russia, India and China (BRIC nations, grouped analysis).

See what's likely to happen. You find areas with highest potential. Also, you investigate reasons for expected revenue growth, especially future PD medication.

Research and development - see trends and possibilities

What about the R&D pipeline for Parkinson's treatment? You assess developmental trends there:• Adenosine receptor antagonists• Glutamatergic drugs• LID treatment options• Agents for non-motor symptoms• Treatment of psychosis• Alleviation of PD sleep disorders• Pain treatment• Nicotinic receptor targeting.

Also, our work covers the disease modification field, including:

• Possible neuroprotectants (including Azilect)

• Biomarkers

• GDNF and other growth factors

• Peptide drugs

• Gene therapies

• Neurotrophic factors and PD treatment with stem cells

• Therapeutic vaccines.

Many opportunities exist for large companies and specialty pharma firms. Our study shows you why and how.

Leading companies and market value in 2016

What will happen next? The pharmaceutical industry will improve treatments for Parkinson's and other neurodegenerative disorders. The R&D pipeline is strong, broad and promising.

Overall world revenue for drugs treating PD will reach $3426m in 2016, our report forecasts. Ageing populations will increase sales of those medicines. Also, improved understanding of the disease, drug delivery and other technological advances will be important.

In our study you find discussions of these companies and others:• Novartis• GlaxoSmithKline (GSK)• Newron• Teva• Addex• Abbott.

Neurological specialists will develop and prosper from 2013. Our work shows you commercial possibilities for those CNS treatments.

Eight main ways Parkinson's Disease: World Drug Market 2013-2023 helps you In particular, then, our investigation gives you the following knowledge on the topic:

• Forecasted revenues to 2023 for the overall world market and 5 submarkets - you discover the industry's future prospects

• Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy and BRIC nations - you see national and regional sales outlooks

• Review of R&D pipelines - you hear about progress in established and emerging research areas and see commercial possibilities

• Opinions on the sector - you discover our interviews with authorities in the field

• Assessment of companies - you find activities, products, strategies and outlooks

• Competition and opportunities influencing sales - you see what affects the future

• Discussions of what stimulates and restrains the industry and market - you assess commercial trends, drivers and restraints

• Prospects for established firms and those seeking to enter the sector - you see factors and outlooks for success.

You gain information found nowhere else That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.

With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.

Discover prospects for Parkinson's treatments by ordering now

Visiongain's study is for everyone needing analysis of the industry and market for treating neurodegenerative disorders. You find data, trends and predictions. Please ask for our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents 1. Executive Summary 1.1 Parkinson's Disease: Market Overview

1.2 Contents of this Report

1.3 Research and Analysis Methods

2. Parkinson's Disease: Overview

2.1 Parkinson's is Characterised by Dopamine Depletion2.2 Motor Symptoms of Parkinson's Disease2.2.1 Tremor2.2.2 Rigidity2.2.3 Bradykinesia2.2.4 Postural Instability2.2.5 Other Motor Symptoms2.3 Cognitive, Behavioural and Other Symptoms2.3.1 Cognitive Deficits2.3.2 Behavioural and Mood Difficulties2.3.3 Other Symptoms2.4 Subtypes and Possible Origin of the Disease2.5 Timeline of Parkinson's Disease Treatment

3. Parkinson's Disease Treatment: Market Overview 2013-2023

3.1 How Much Growth Can Be Expected in the Parkinson's Disease Market, 2013-2023?

3.1.1 Overall Market Forecast for 2012-2023

3.2 Three Franchises Held 60% of the Market in 2011

3.2.1 Mirapex Drops Back in 2011

3.2.2 Patent Protection is Nearly at an End for the Leading Drugs

3.2.3 Important Generic Launches in 2011-2012

3.3 The Three Market Leaders: Overview

3.3.1 Comtan/Stalevo: Leading Parkinson's Disease Drug

3.3.2 Requip: Leading the Dopamine Agonist Segment

3.3.3 Azilect: Set to Become Market Leader Azilect: The First Neuroprotectant?

3.4 Leading Companies in the Parkinson's Disease Treatment Market

4. Leading National Markets, 2013-2023

4.1 The EU5 Represented the Largest Regional Parkinson's Disease Market in 20114.2 The BRIC Nations Will Be the Fastest-Growing Region in the Forecast Period4.3 The US Represents a Quarter of the Market4.3.1 Market Projection for the US, 2012-20234.4 EU5: Ageing Populations and Fiscal Restrictions4.4.1 Market Projection for the EU5 Group, 2012-20234.4.2 Breakdown of the EU5 by Country, 20114.4.3 Changes in Market Shares of the EU5 Countries, 2012-20234.4.4 Germany 2012-2023: The Largest EU5 Market4.4.5 France 2012-2023: EU5's Highest Healthcare Spender 4.4.6 UK 2012-2023: Spending Restrictions4.4.7 Spain 2012-2023: Facing Significant Cost-Containment Measures4.4.8 Italy 2012-2023: One in Five People Are Over 654.5 Japan 2012-2023: Second-Largest National Market in 20124.5.1 Market Projection for Japan, 2012-20234.6 BRIC Nations: The Rapid-Growth Area for Pharma4.6.1 Market Projection for the BRIC Nations Group 2012-2023

5. Market Segments for Treatment of Parkinson's Disease, 2013-2023

5.1 Dopamine Receptor Agonists: the Leading Class of Drug in 2011

5.2 How Will the Balance of Market Share Shift During the Forecast Period?

5.3 Dopaminergic Agents: The Foundation of Parkinson's Disease Treatment

5.3.1 Levodopa and Carbidopa

5.3.2 Brands of Dopaminergic Agent

5.3.3 Use of Dopaminergic Agents Will Remain Central to Parkinson's Disease Management

5.3.4 A New Commercial Life for Dopaminergic Agents?

5.3.5 Market Projection for Dopaminergic Agents, 2012-2023

5.4 Dopamine Receptor Agonists: The Leading Class in 2011

5.4.1 Mechanism of Action Makes Dopamine Receptor Agonists a Good First-Line Therapy

5.4.2 Multiple Products Exist in the Dopamine Receptor Agonists Class

5.4.3 A Thin Pipeline in this Segment

5.4.4 Commercial Opportunities for Dopamine Receptor Agonists

5.4.5 Market Projection for Dopamine Receptor Agonists, 2012-2023

5.5 COMT Inhibitors: The Segment with the Leading Product in 2011

5.5.1 COMT Inhibitors as Adjuncts to Dopaminergic Agents

5.5.2 Limitations of COMT Inhibitors

5.5.3 Future Commercial Scope for COMT Inhibitors

5.5.4 Market Projection for COMT Inhibitors, 2012-2023

5.6 MAO Inhibitors: A Growing Segment

5.6.1 Another Useful Adjunct to Levodopa

5.6.2 MAO Inhibitors Have Advantages over COMT Inhibitors

5.6.3 Potential for New Growth in the Sector

5.6.4 Market Projection for MAO Inhibitors, 2012-2023

5.7 Other Mechanisms of Action: The Major Driver for the Market

5.7.1 A Broad and Diverse Segment

5.7.2 The Key New Mechanisms of Action

5.7.3 Market Projection for Other Mechanisms of Action, 2012-2023

6. R&D Pipeline for Treating Parkinson's Disease, 2012

6.1 New Mechanisms of Action in the Late-Stage Pipeline6.2 The Phase 3 Pipeline: Overview6.3 Rytary (Impax Laboratories): The Next Version of Levodopa to Reach the Market6.3.1 FDA Delays Until January 20136.3.2 Will Impax Make an Impact in PD in 2013?6.3.3 Back to Basics: Reformulating Levodopa as a PD R&D Strategy6.4 Safinamide (Newron): New MAO Inhibitor with Multiple Mechanisms of Action6.4.1 Safinamide Partnerships6.4.2 Commercial Prospects for Safinamide6.4.3 New Versions of Existing PD Mechanisms of Action6.5 Istradefylline (Kyowa Hakko Kirin): First-in-Class A2A Receptor Antagonist6.5.1 Will Istradefylline Be Launched Outside Japan?6.5.2 Apokyn: Kyowa Hakko Kirin's Other PD Programme6.5.3 Adenosine Receptor Antagonists: A New Option in PD Treatment6.6 Levodopa-Carbidopa Intestinal Gel (Abbott Laboratories)6.6.1 An Expensive Option? 6.7 ACP-103 (Acadia Pharmaceuticals)6.7.1 PD Psychosis: A Major Unmet Need6.7.2 No Motoric Side-Effects, But Can ACP-103 Show Antipsychotic Efficacy?6.7.3 Treating the Non-Motor Symptoms of PD: Another Important Pipeline Theme6.8 Opicapone (Bial - Portela)6.9 Preladenant (Merck): The First Adenosine Receptor Antagonist to Reach Ex-Japanese Markets?6.9.1 The Adenosine Receptor Antagonist with the Highest Market Potential?6.10 Pitolisant (Bioprojet Pharma): The First Treatment for PD Sleep Disorders?6.11 Northera (Chelsea Therapeutics): Another Possible Symptomatic Treatment6.11.1 Established in the Japanese Market for 20+ Years6.11.2 Orphan Treatment for Common PD Symptom6.11.3 Northera's Road to Approval Blocked?6.12 Oxycodone/Naxolone (Mundipharma Research): Severe Pain Drug May Meet Unmet Need in PD6.12.1 Pain in PD: Another Symptom that Needs to be Addressed6.13 SYN115 (Biotie Therapies): Another Adenosine Receptor Antagonist in the Race to Market6.13.1 Could SYN115 Become the Best-in-Class?6.13.2 SYN118: A Second Candidate6.14 Nurelin (Adamas Pharmaceuticals): A New LID Treatment Option6.14.1 A New Twist on an Established Drug6.14.2 Glutamatergic Drugs Have the Highest Potential of Any of the Near-Term Pipeline Products6.15 The Phase 2 Pipeline: Overview6.16 AFQ056 (Novartis): First mGLuR5 Antagonist to Market?6.16.1 The New Generation of Glutamatergic Drugs6.16.2 AFQ056 vs. Dipraglurant6.16.3 AQW051: Novartis Also Targeting Nicotinic Receptors6.16.4 Nicotinic Receptor Targeting6.17 Dipraglurant-IR (Addex Therapeutics): Competing for the mGluR5 Market6.17.1 Allosteric Modulators: An Emerging New Approach6.17.2 Can Dipraglurant Become a New PD Blockbuster?6.17.3 ADX88178 (Addex Therapeutics)6.17.4 Domain Therapeutics: Targeting the Same Therapeutic Approach6.18 Fipamezole (Santhera Pharmaceuticals): Another Challenger in the A2a Antagonist Space6.19 CVT-301 (Civitas Therapeutics): Levodopa for the Deep Lung6.20 DM-1992 (Depomed): Gastric Retention Levodopa6.21 Accordion Pill Carbidopa/Levodopa (Intec Pharma): Another Option to Reduce Levodopa Dosing Needs6.22 Oxybutynin and Clonidine Oral Solution (Orient Pharma): Treatment for Sialorrhoea6.22 Sialorrhoea: A Socially Difficult Symptom of PD6.23 NH004 (NeuroHealing) 6.24 VR040 (Vectura Group)6.25 XP21279 (XenoPort)6.26 The Phase 1 and Preclinical Pipeline: Overview6.26.1 ND0611 (Neuroderm) 6.27 Neu-120 (Neurim Pharmaceuticals)6.28 Ordopidine (Neurosearch)6.29 ProNeura Continuous Release Dopamine Agonist (Titan Pharmaceuticals)6.30 V81444 (Vernalis): Regained Rights from Biogen Idec6.31 AVE8112 (Sanofi/MJFF)6.32 SKL-PD (SK Biosciences)

7. The Next Frontier in PD Treatment: Disease-Modifying Treatments R&D Pipeline

7.1 Disease Modification and Neuroprotection: Basic Concepts

7.1.1 Why Do Cells Die in PD and What Would Stop Them?

7.2 Azilect: the Leading Candidate Neuroprotectant Among Existing Approved Drugs

7.2.1 Azilect's Presumed Neuroprotective Mechanisms of Action

7.2.2 How can Neuroprotective Effects be Measured?

7.2.3 Early Interventions and Delayed Starts

7.2.4 'This is Close, But It's Not Good Enough': The ADAGIO Trial Verdict

7.2.5 Where Does the Failure of the Azilect Trial Leave the Disease Modification Concept?

7.3 How Will We Know Disease Modification if We See It? Progress in Biomarkers, Imaging and Disease Models

7.3.1 The $30m Search for PD Biomarkers

7.3.2 When Will We Have Robust PD Biomarkers?

7.3.3 Players in the PD Biomarkers Field

7.3.4 SPECT, PET and MRI: Shining a Light on PD

7.3.5 Disease Process, not Disease Endstage: New Animal Models for Disease Modification

7.4 Candidates for Disease Modification: Pipeline Overview

7.5 Coenzyme Q10 (National Institute of Neurological Disorders and Stroke [NINDS])

7.5.1 A Nutritional Supplement with Limited Commercial Scope

7.5.2 Nearly Two Decades of Investigation

7.5.3 Dietary Supplements as Disease Modifiers

7.6 Repurposing Existing Drugs for PD

7.7 Exenatide (University College London)

7.7.1 Rationale for Repurposing Exenatide

7.8 Isradipine (The Parkinson Study Group)

7.8.1 Blocking Brain Calcium Channels

7.9 Other Possible Small-Molecule Disease-Modifying Agents

7.10 Cogane (Phytopharm)

7.10.1 Cogane's Possible Disease-Modification Mechanism

7.10.2 One of the Leading Small Molecules in the Disease Modification Hunt

7.11 AZD3241 (AstraZeneca): First Myeloperoxidase Inhibitor in PD Trials

7.12 AT2101/AT3375 (Amicus Therapeutics): Innovative 'Pharmacological Chaperone'

7.13 VAR 10300 (Varinel): Virtual Company's Possible PD Candidate

7.13.1 Multiple Mechanisms of Action

7.14 NP001 (Neuraltus)

7.15 XP23829 (XenoPort): A Promising Prodrug

7.16 GDNF and Other Growth Factors: A Neglected Possibility?

7.17 MANF (Amarantus BioSciences): A Future Biological Blockbuster?

7.18 Peptide Drugs

7.19 GM6 (Genervon Biopharmaceuticals)

7.19.1 Impressive Animal Model Results

7.20 NNZ-2591 (Neuren Pharmaceuticals)

7.21 Davunetide (Allon Therapeutics)

7.22 Gene Therapies

7.23 ProSavin (Oxford BioMedica)

7.23.1 ProSavin Clinical Trials Performance to Date

7.23.2 Will ProSavin Lead The Charge In PD Gene Therapy?

7.24 CERE-120 (Ceregene): Delivering Neurotrophic Factors

7.24.1 Repairing Dopaminergic Neurons in Human Beings

7.24.2 Can New Trial Succeed Where Past Attempts Failed?

7.25 AAV-hAADC-2 (Genzyme): AAV Gene Therapy Due to Complete Phase 1 in Q1 2013

7.26 Collategene (Vical/AnGes): Angiogenic Gene Therapy

7.27 AAV2-GDNF (uniQure)

7.28 Cellular Therapies

7.29 Spheramine (Bayer): RPE Cells to Make Levodopa

7.30 NTCELL (Living Cell Technologies)

7.31 Stem Cell Approaches to PD

7.32 NeuroGeneration - PD Treatment with Autologous Neural Stem Cells

7.33 BrainStorm Cell Therapeutics - Proprietary NurOwn Cells

7.34 Therapeutic Vaccine Approaches

7.35 Affitope PD01 (Affiris) - The First Vaccine for PD

8. Qualitative Industry Analysis: Drivers and Restraints

8.1 Strengths: Parkinson's Disease is a Prevalent and Treatable Disease8.2 Weaknesses: Products on the Market Have Limitations and Can Be Superseded8.3 Opportunities: Neurodegenerative Disorder Treatments Are a Fertile R&D Area8.4 Threats: New Parkinson's Treatments May Be Subject to Political, Commercial and Social Pressures

9. Interviews

9.1 Interview with Dr Kieran Breen , Parkinson's UK

9.1.1 Repositioning Drugs, and Bigger Databases: Developments in the PD Market in 2011-2012

9.1.2 The New Non-Dopaminergic Drugs

9.1.3 The Challenge of Disease Modification

9.1.4 New Formulations of Levodopa

9.1.5 The Next Decade for Parkinson's Disease

9.2 Interview with Chris Maggos , Addex Therapeutics

9.2.1 What Differentiates Addex's Candidates?

9.2.2 Understanding the Glutamatergic Approach

9.2.3 Dipraglurant's Progress

9.2.4 How Glutamatergic Drugs Might Change the Treatment Paradigm

9.2.5 Other Addex Programmes

9.2.6 What Will the Next Decade Bring in PD Treatment?

9.3 Interview with Dr Marie Chesselet , University of California, Los Angeles(UCLA)

9.3.1 Current Understanding of Parkinson's Disease Genetic Basis

9.3.2 Challenges of Animal Models

9.3.3 Disease Modification Possibilities

9.3.4 Bringing New Research to the Clinic

9.4 Interview with Mr Larry Glass , Neuren Pharmaceuticals

9.4.1 Failure of Clinical Trials Testing Neuroprotective Agents

9.4.2 Neuroprotective Agent - NNZ-2566

9.4.3 Sub-classes of Neuroprotective Agents

9.4.4 Promising Neuroprotective Agents

9.4.5 Potential of Neuroprotective Agents

10. Conclusions

10.1 The PD Market is Set for an Important Transition in the Forecast Period10.2 New Classes of Parkinson's Disease Drug to Emerge by 201310.3 Disease Modification Remains the Goal10.4 Strong Underlying Factors Drive Growth in this Market

List of Tables Table 2.1 Timeline of Parkinson's Disease

Table 3.1 Parkinson's Disease Market: Revenues ($m), AGR (%), CAGR (%), 2011-2016

Table 3.2 Parkinson's Disease Market: Revenues ($m), AGR (%), CAGR (%), 2017-2023

Table 3.3 PD Market: Leading Drugs, Revenues ($m), Market Shares (%), 2011

Table 3.4 Leading PD Drugs: US Patent Expiry Dates

Table 3.5 PD Market: Leading Companies, Revenues ($m), Market Shares (%), 2011

Table 4.1 PD Market Breakdown by Region: Revenues ($m), Market Shares (%), 2011

Table 4.2 PD Market Breakdown by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.3 PD Market Breakdown by Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.4 US Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.5 US Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.6 EU5 Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.7 EU5 Region: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.8 EU5 Region Breakdown by Country: Revenues ($m), Market Shares (%), 2011

Table 4.9 EU5 Region Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.10 EU5 Region Breakdown by Country: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.11 Germany: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.12 Germany: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.13 France: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.14 France: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.15 UK: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.16 UK: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.17 Spain: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.18 Spain: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.19 Italy: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.20 Italy: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.21 Japan: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.22 Japan: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 4.23 BRIC Nations: Grouped Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 4.24 BRIC Nations: Grouped Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.1 PD Market Breakdown by Segment: Revenues ($m), Market Shares (%), 2011

Table 5.2 PD Market Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 5.3 PD Market Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.4 Selected Dopaminergic Agents, 2012

Table 5.5 Dopaminergic Agents Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%) 2011-2016

Table 5.6 Dopaminergic Agents Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.7 Selected Dopamine Receptor Agonists, 2012

Table 5.8 Dopamine Receptor Agonists Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 5.9 Dopamine Receptor Agonists Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.10 COMT Inhibitors Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 5.11 COMT Inhibitors Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.12 MAO Inhibitors Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 5.13 MAO Inhibitors Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 5.14 Other Mechanisms of Action Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 5.15 Other Mechanisms of Action Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023

Table 6.1 Selected Phase 3 PD Pipeline, 2012

Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Pipeline Development, 2012

Table 6.3 Pipeline Candidates with Established Mechanisms of Action, 2012

Table 6.4 Pipeline Adenosine 2a Receptor Antagonists, 2012

Table 6.5 Pipeline Candidates for Non-Motor PD Symptoms, 2012

Table 6.6 Pipeline Candidates for Motor PD Symptoms, 2012

Table 6.7 Pipeline Glutamatergic Drugs, 2012

Table 6.8 Selected Phase 2 PD Pipeline, 2012

Table 6.9 Pipeline Nicotine Receptor Agonists, 2012

Table 6.10 Allosteric Modulators in Development for PD, 2012

Table 7.1 Trials of PD Drugs as Neuroprotectants, 2012

Table 7.2 Selected Possible Disease-Modifying Agents under Investigation in PD, 2012

Table 7.3 Selected Dietary Supplements in the PD Pipeline, 2012

Table 7.4 Selected Repurposed Drugs in the PD Pipeline, 2012

Table 7.5 Selected Small-Molecule Drugs in the PD Pipeline, 2012

Table 7.6 Selected Peptide Drugs in the PD Pipeline, 2012

Table 7.7 Selected Gene Therapies in the PD Pipeline, 2012

Table 7.8 Selected Cellular Therapies in the PD Pipeline, 2012

List of Figures Figure 2.1 The Five Stages of Parkinson's Disease

Figure 3.1 PD Market: Revenues ($m), 2011-2023

Figure 3.2 PD Market: Leading Drugs, Revenues ($m), Market Shares (%), 2011

Figure 3.3 Azilect: Projected PD Market Shares (%), 2013-2023

Figure 3.4 PD Market: Leading Companies, Revenues ($m), Market Shares (%), 2011

Figure 4.1 PD Market Breakdown by Region: Revenues ($m), Market Shares (%), 2011

Figure 4.2 PD Market Breakdown by Region: Revenues ($m), 2011-2023

Figure 4.3 US Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.4 US Region: Revenues ($m), 2011-2023

Figure 4.5 EU5 Region: Revenues ($m), 2011-2023

Figure 4.6 EU5 Region Breakdown by Country: Revenues ($m), Market Shares (%), 2011

Figure 4.7 EU5 Breakdown by Country: Revenues ($m), 2011-2023

Figure 4.8 Germany: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.9 Germany Region: Revenues ($m), 2011-2023

Figure 4.10 France: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.11 France: Revenues ($m), 2011-2023

Figure 4.12 UK: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.13 UK: Revenues ($m), 2011-2023

Figure 4.14 Spain: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.15 Spain: Revenues ($m), 2011-2023

Figure 4.16 Italy: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.17 Italy: Revenues ($m), 2011-2023

Figure 4.18 Japan: Over-65 Population as Percentage of Overall Population, 2011-2023

Figure 4.19 Japan: Revenues ($m), 2011-2023

Figure 4.20 BRIC Nations: Grouped Revenues ($m), 2011-2023

Figure 5.1 PD Market Breakdown by Segment: Revenues ($m), Market Shares (%), 2011

Figure 5.2 PD Market Breakdown by Segment: Revenues ($m), 2011-2023

Figure 5.3 Drivers and Restraints for Dopaminergic Agents, 2012

Figure 5.4 Dopaminergic Agents Segment: Revenues ($m), 2011-2023

Figure 5.5 Drivers and Restraints for Dopamine Receptor Agonists, 2012

Figure 5.6 Dopamine Receptor Agonists Segment: Revenues ($m), 2011-2023

Figure 5.7 Drivers and Restraints for COMT Inhibitors, 2012

Figure 5.8 COMT Inhibitors Segment: Revenues ($m), 2011-2023

Figure 5.9 Drivers and Restraints for MAO Inhibitors, 2012

Figure 5.10 MAO Inhibitors Segment: Revenues ($m), 2011-2023

Figure 5.11 Other Mechanisms of Action Segment: Revenues ($m), 2011-2023

Figure 10.1 PD Market: Overall Revenues ($m), 2011, 2016 and 2023

Figure 10.2 PD Market Revenues by Segment ($m), 2011, 2016 and 2023

Companies Listed Abbott Laboratories

Acadia Pharmaceuticals

Adamas Pharmaceuticals

Addex Therapeutics


Allon Therapeutics

Amarantus BioSciences


Amicus Therapeutics

Amylin Pharmaceuticals


Ark Therapeutics


Axxonis Pharma


BIAL - Portela

Biogen Idec

Bioprojet Pharma

BioSante Pharmaceuticals

Biotie Therapies


Boehringer Ingelheim

BrainStorm Cell Therapeutics

Buck Institute for Research on Ageing


Chelsea Therapeutics



Civitas Therapeutics

Columbia University

Dainippon Sumitomo




Domain Therapeutics

Dr. Reddy's Laboratories

Dresden University of Technology

Durin Technologies


EMD Serono

Endo Pharmaceuticals


European Medicines Agency (EMEA/EMA)

Farmitalia Carlo

Food and Drug Administration (US FDA)

Genervon Biopharmaceuticals


GlaxoSmithKline (GSK)

Impax Pharmaceuticals (Impax Laboratories)

Intec Pharma


Juvantia Pharma

Kaneka Nutrients

Kyoto University

Kyowa Hakko Kirin

Living Cell Technologies


Maypro Industries

Meiji Seika

Merck & Co.

Merck KGaA

Merck Serono

Mitsubishi Gas Chemical

Mount Sinai School of Medicine

Mundipharma Research


Napp Pharmaceuticals

National Health Service (NHS, UK)

National Institute for Health and Clinical Excellence (NICE, UK)

National Institute of Neurological Disorders and Stroke (NINDS, US)

National Institutes of Health (NIH, US)



Neuren Pharmaceuticals

Neurim Pharmaceuticals









Orient Pharma


Oxford BioMedica

Pacific Rainbow International

Parkinson's UK





Power3 Medical Products






Schering Plough


ShenZhou Biology & Technology

SK Biosciences

Solvay Pharmaceuticals


Swedish Orphan Biovitrum

Synergen Corporation

Synosia Therapeutics

Technion-Israel Institute of Technology

Tel Aviv University

Teva Pharmaceutical Industries

The Michael J. Fox Foundation

Titan Pharmaceuticals



University College London (UCL)

University of Bristol Institute of Clinical Neuroscience

University of California, Los Angeles (UCLA)

University of Kentucky

University of Nebraska

University of Rochester



Vectura Group



Watson Pharmaceuticals



Xiamen Kingdomway Group


Zhejiang Medicine Company

To order this report:Drug_and_Medication Industry: Parkinson`s Disease: World Drug Market 2013-2023

Contact Clare:
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generic Drugs: World Market 2013-2023
2. Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes
3. Healthcare Innovation World Cup: Innovative Ideen zur Bekämpfung von Diabetes gesucht
4. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
5. Research Units Across the World go for the First 3 Tesla, Cryogen Free MRI Bench Top Scanner
6. Computed Tomography (CT): Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2018
7. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
8. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
9. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
10. Randy Gaboriault of Christiana Care Health System Named Computerworld Premier 100 IT Leader
11. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
Post Your Comments:
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 On ... the NASDAQ Composite closed the trading session up 0.19%; ... the S&P 500 was down 0.08%. US markets made ... finishing the day in green. Pre-market today, reviews ... Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology:
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... restoration treatment, is proud to announce a new blog post about women’s hair loss. ... women suffer from hair loss as they age. Menopause or genetics can be two ...
(Date:3/28/2017)... Louis, MO (PRWEB) , ... March 28, 2017 ... ... levels of job satisfaction in their profession as their value increases in the ... company that provides resources such as job boards, career fairs, and candidate leads ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... ... March 27, 2017 , ... This ... OSEHRA popHealth Community in 2014. It is the culmination of collaborative ... Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification ...
Breaking Medicine News(10 mins):